Stocktoria

CG Oncology, Inc. CGON

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-01-25

CG Oncology, Inc. statistics & valuation

Market cap$6.3B
P / B8.4×
Net margin-3985.0%
Return on equity-21.4%
FCF margin-3279.2%
Net cash$29.5M
Enterprise value USD$6.3B
Earnings yield EBIT/EV-3%
Return on capital-25.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-23827.00% -7729.50% -3985.00% 202320242025
Gross margin (%)
202320242025
Operating margin (%)
-27180.90% -10067.30% -4722.10% 202320242025
Return on equity (%)
-12.00% -21.40% 202320242025
Shares outstanding
5.2M 76.2M 80.7M 202320242025
Net debt ($)
-$257.1M -$29.5M 202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-24.40% -11.70% -20.30% 202320242025
Free cash flow margin (%)
-6931.30% -3279.20% 202320242025
Debt / equity (×)
0.00× 0.00× 202320242025
EPS ($)
-$15.65 -$1.41 -$2.08 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Operating margin-4722.1%-10067.3%-27180.9%
Net margin-3985.0%-7729.5%-23827.0%
FCF margin-3279.2%-6931.3%—
Return on assets-20.3%-11.7%-24.4%
Return on equity-21.4%-12.0%39.5%
Debt / equity0.00×0.00×—
Current ratio24.6335.3013.62

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.